Clearmind Medicine (CMND) said it has enrolled the first patient for its phase 1/2a clinical trial of CMND-100, an oral drug candidate aimed at treating alcohol use disorder.
The trial is aimed at assessing the safety, tolerability, and pharmacokinetic effects of CMND-100 in potentially reducing alcohol cravings and consumption, the clinical-stage company said.
Shares of the company were up 6% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。